Cart
sales@molnova.com
TIBI
CAS No. 1196457-06-3
TIBI( —— )
Catalog No. M34446 CAS No. 1196457-06-3
TIBI is an ATP-competitive Rio1 inhibitor that acts in a similar manner to fungamycin and enhances the thermal stability of the enzyme.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 85 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTIBI
-
NoteResearch use only, not for human use.
-
Brief DescriptionTIBI is an ATP-competitive Rio1 inhibitor that acts in a similar manner to fungamycin and enhances the thermal stability of the enzyme.
-
DescriptionTIBI is a potent and ATP-competitive inhibitor of Rio1 (IC50: 0.09 μM, Ki: 0.05 μM). TIBI enhances the thermostability of the enzyme Rio1.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1196457-06-3
-
Formula Weight621.72
-
Molecular FormulaC7H2I4N2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (80.42 mM; Ultrasonic )
-
SMILESIC=1C(I)=C(I)C=2NC=NC2C1I
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kubiński K, et al. Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase Rio1. Mol Cell Biochem. 2017 Feb;426(1-2):195-203.?
molnova catalog
related products
-
Exendin-4 peptide de...
FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.Exendin-4 peptide derivatives are structurally derived from Exendin-4 and may relates to dual GLP-1/glucagon receptor agonists.
-
S Tag Peptide
S Tag Peptide is a 15 amino acid peptide derived from RNase A.
-
Salvianan
Salviane exhibits the most potent cytotoxicity with a CD50 range of 30.4-39.5 microM against HeLa (cervical epitheloid carcinoma), HepG2 (hepatocellular carcinoma), and OVCAR-3 (ovarian adenocarcinoma) cell lines in a dose-dependent manner.
